哌拉嗪与利培酮的CYP450介导相互作用:对精神科联合用药的启示
本研究利用治疗药物监测数据库,比较利培酮单药治疗组(n=40)与联用哌拉嗪组(n=16)的血药浓度及代谢比率。结果显示联用哌拉嗪组利培酮及活性部分浓度与剂量校正浓度显著升高,代谢比率降低,提示哌拉嗪抑制CYP2D6和CYP3A4活性,增加药物相互作用风险。
要点
- 联用哌拉嗪使利培酮及活性部分血药浓度和C/D显著升高。
- 联用哌拉嗪组9-OH-RIS/RIS代谢比率显著降低。
- 机制可能为哌拉嗪抑制CYP2D6和CYP3A4活性。
核心结论
- 联用哌拉嗪使利培酮及其活性部分的血药浓度和剂量校正浓度显著升高,代谢比率降低。
研究设计与样本
- 基于治疗药物监测数据库的回顾性研究,利培酮单药组n=40,联用哌拉嗪组n=16,两组按人口学特征和利培酮日剂量匹配。
主要发现
- 联用哌拉嗪组活性部分血药浓度中位数和C/D中位数均高于单药组(P < 0.001和P < 0.001)。
- 联用哌拉嗪组利培酮血药浓度和C/D均高于单药组(P < 0.001和P < 0.001)。
- 联用哌拉嗪组9-OH-RIS/RIS代谢比率低于单药组(P = 0.003)。
- 两组间9-OH-RIS的血药浓度和C/D无差异。
临床怎么用
- 联合使用哌拉嗪与利培酮时,应警惕利培酮暴露量增加及相关不良反应风险。
- 建议对联用患者进行治疗药物监测,必要时调整利培酮剂量。
局限性
- 研究样本量有限,联用哌拉嗪组仅16例。
- 回顾性设计可能受混杂因素影响。
- 机制推测基于代谢比率变化,未直接进行酶活性测定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although clinically widespread, scientific evidence for antipsychotic polypharmacy is still limited. Combining different drugs increases the potential for drug-drug interactions, enhancing the risk of adverse drug reactions. We aimed to unravel the potential pharmacokinetic interactions between risperidone (RIS) and perazine. METHODS: Using a therapeutic drug monitoring database containing plasma concentrations of RIS and its active metabolite [9-hydroxyrisperidone (9-OH-RIS)], we considered two groups: a group of patients under antipsychotic monotherapy with RIS (n = 40) and a group of patients that was comedicated with perazine (n = 16). Groups were matched for demographic characteristics and daily dosage of RIS. Plasma concentrations, concentrations corrected for the dose (C/D) of RIS, 9-OH-RIS and the active moiety (RIS + 9-OH-RIS), as well as the metabolic ratios of concentrations of 9-OH-RIS/RIS, were compared using nonparametric tests. RESULTS: All parameters other than plasma concentrations and the C/D ratio of 9-OH-RIS differed between groups. Median values for plasma concentrations of the active moiety and C/D of the active moiety were higher in the perazine group (P < 0.001 and P < 0.001, respectively). Differences were driven by variations in the plasma concentrations and C/D of RIS, which were higher in the perazine group (P < 0.001 and P < 0.001, respectively). Metabolic ratios were lower in the perazine group (P = 0.003). DISCUSSION: The coadministration of perazine in RIS-medicated patients leads to significantly higher plasma concentrations and C/D values of RIS and its active moiety, and a lower metabolic ratio, reflecting the cytochrome P450 (CYP) 2D6 phenotype. We suggest that the mechanism underlying the effect of perazine on RIS metabolism is based on an inhibition of CYP2D6 and CYP3A4 activity.
引用
- Paulzen M, Haen E, Hiemke C, et al. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol. 2017. PMID: 28160505. doi:10.1111/bcp.13255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。